Author

Angelika Gawlik-Urban

Observed names: A. Gawlik-Urban, A.K. Gawlik-Urban, Gawlik-Urban, Angelika

Institutions: Akademia Tarnowska, The Maria Sklodowska-Curie National Research Institute of Oncology

Observed institutions: Akademia Tarnowska, The Maria Sklodowska-Curie National Research Institute of Oncology

ORCID: 0000-0003-1396-1196

Observed ORCID: 0000-0003-1396-1196

OpenAlex ID: A5016011058

Attitudes of Patients with Cancer towards Vaccinations—Results of Online Survey with Special Focus on the Vaccination against COVID-19

2021 · Anna Brodziak, Dawid Sigorski, et al. · Vaccines · 82

Prevalence and factors associated with professional burnout in Polish oncologists—results of a nationwide survey

2024 · P. Sobczuk, A. Gawlik-Urban, et al. · ESMO Open · 18

Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab—a polish multicenter, observational study

2025 · Renata Pacholczak-Madej, Artur Drobniak, et al. · Clinical and Experimental Medicine · 10

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland

2023 · Dawid Sigorski, Michał Wilk, et al. · Frontiers in Oncology · 5

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland

2025 · Artur Drobniak, Łukasz Stokłosa, et al. · Frontiers in Oncology · 1

Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study

2025 · Renata Pacholczak-Madej, Artur Drobniak, et al. · Future Oncology · 1

1442P Prevalence and factors associated with professional burnout in Polish oncologists: A nationwide survey by Young Oncologists Section of Polish Society of Clinical Oncology

2022 · P. Sobczuk, A. Gawlik-Urban, et al. · Annals of Oncology · 1

60eP Cemiplimab in recurrent/metastatic cervical cancer: Real-world outcomes from a multicenter Polish-Czech cohort (PCCIG-03 study)

2026 · R. Pacholczak-Madej, R. Lupkowski, et al. · ESMO Open

Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer—Data from the Polish–Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature

2026 · Radosław Łupkowski, Karolina Górniak, et al. · Antibodies

Works count: 10

Citation count: 118

H-index: 4

I10-index: 3